Intermediate-Risk NMIBC/BCG Naïve: Treatment of Choice
Leonard G. Gomella, MD, FACS, explores bladder cancer treatment, particularly in the context of intermediate-risk, BCG-naïve disease.
Read MoreSelect Page
Posted by Leonard G. Gomella, MD, FACS | May 2025
Leonard G. Gomella, MD, FACS, explores bladder cancer treatment, particularly in the context of intermediate-risk, BCG-naïve disease.
Read MorePosted by Jay Simhan, MD, FACS | May 2025
Jay Simhan, MD, FACS, examines the challenges of penile implants in patients with refractory erectile dysfunction and Peyronie’s disease.
Read MorePosted by Ariana L. Smith, MD | Apr 2025
Ariana L. Smith, MD, highlights the achievements of the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium.
Read MorePosted by Jay Simhan, MD, FACS | Apr 2025
Jay Simhan, MD, FACS, explores the challenges of post-radiation bladder neck and proximal urethral strictures.
Read MorePosted by Diane Newman, DNP ANP-BC FAAN FAUNA BCB-PMD | Apr 2025
Jill Peters-Gee, MD, presents a comprehensive overview of interstitial cystitis, focusing on phenotyping as a diagnostic and therapeutic strategy.
Read More